BINSA Act

Key Points

• The bill adds biotechnology, including drugs, biologics, and therapeutic compounds, to the list of technologies covered by the government's outbound investment screening program, meaning some deals with foreign entities would need government notice or approval.
• Lawmakers say U.S. capital and know-how flowing to Chinese biotech firms through licensing deals, joint ventures, and stock investments is helping China dominate global pharmaceutical development, creating a strategic dependency risk similar to computer chips.
• In 2025 alone, cross-border licensing deals between U.S./European drugmakers and Chinese biotech firms totaled about $136 billion, a figure Congress cites as evidence of how fast this transfer of capability is happening.
• The bill specifically protects agricultural biotechnology, unrelated industrial fermentation, and basic academic research from being swept into the new restrictions, so farmers and university researchers should not be directly affected.
• The Treasury Department would have one year after enactment to write detailed rules defining which biotech deals count as prohibited or notifiable, consulting with health, defense, and intelligence agencies.
• Within 60 days of the bill becoming law, the Defense Department must report to Congress on whether U.S. money flowing into China's biotech sector threatens national security and military readiness.